Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (KCT0012590) titled 'A Multicenter Clinical Study Evaluating the Safety and Efficacy of Autologous Natural Killer Cells (CHANK-101) in Patients with Recurrent Glioblastoma' on Sept. 9.
Study Type: Interventional Study
Study Design:
Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable
Primary Sponsor: Dong-A University Hospital
Condition:
Neoplasms
Intervention:
Biological/Vaccine, Non-Stem Cell : 1. Intervention Name: Autologous peripheral blood-derived natural killer cells (CHANK-101)
2. Dose: 2-6 x 10^9 cells per administration
3. Frequency: Every 2 weeks for up t...